Literature DB >> 11604389

Suppression of tumor-related glycosylation of cell surface receptors by the 16-kDa membrane subunit of vacuolar H+-ATPase.

M A Skinner1, A G Wildeman.   

Abstract

The glycosylation of integrins and other cell surface receptors is altered in many transformed cells. Notably, an increase in the number of beta1,6-branched N-linked oligosaccharides correlates strongly with invasive growth of cells. An ectopic expression of the Golgi enzyme N-acetylglucosaminyltransferase V (GlcNAc-TV), which forms beta1,6 linkages, promotes metastasis of a number of cell types. It is shown here that the 16-kDa transmembrane subunit (16K) of vacuolar H(+)-ATPase suppresses beta1,6 branching of beta(1) integrin and the epidermal growth factor receptor. Overexpression of 16K inhibits cell adhesion and invasion. 16K contains four hydrophobic membrane-spanning alpha-helices, and its ability to influence glycosylation is localized primarily within the second and fourth membrane-spanning alpha-helices. 16K also interacts directly with the transmembrane domain of beta(1) integrin, but its effects on glycosylation were independent of its binding to beta(1) integrin. These data link cell surface tumor-related glycosylation to a component of the enzyme responsible for acidification of the exocytic pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11604389     DOI: 10.1074/jbc.M103569200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  2 in total

1.  The binding site of the V-ATPase inhibitor apicularen is in the vicinity of those for bafilomycin and archazolid.

Authors:  Christin Osteresch; Tobias Bender; Stephanie Grond; Paultheo von Zezschwitz; Brigitte Kunze; Rolf Jansen; Markus Huss; Helmut Wieczorek
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

2.  Beta1-6 branching of cell surface glycoproteins may contribute to uveal melanoma progression by up-regulating cell motility.

Authors:  Małgorzata Przybyło; Ewa Pocheć; Paweł Link-Lenczowski; Anna Lityńska
Journal:  Mol Vis       Date:  2008-03-26       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.